APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vector-Based RNAi

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vector-Based RNAi Industry Growth and Trends Forecast to 2032

31 December 2025101 pages

Choose your research edition.

Industry ResearchVector-Based RNAi Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Vector-Based RNAi Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Vector-Based RNAi Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vector-Based RNAi Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Vector-Based RNAi Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vector-Based RNAi market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vector-Based RNAi include Alnylam Pharmaceuticals, Arcturus Therapeutics, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Ionis Pharmaceutical, Phio Pharmaceutical, Qiagen NV, Quark Pharmaceuticals and Silence Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vector-Based RNAi market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vector-Based RNAi market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vector-Based RNAi market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vector-Based RNAi.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vector-Based RNAi market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vector-Based RNAi Market by Company

Alnylam Pharmaceuticals

Arcturus Therapeutics

Arrowhead Pharmaceuticals

Dicerna Pharmaceuticals

Ionis Pharmaceutical

Phio Pharmaceutical

Qiagen NV

Quark Pharmaceuticals

Silence Therapeutics

Merck & Co.

Thermo Fisher Scientific

Vector-Based RNAi Segment by Type

Custom siRNA Construction

siRNA Vectors

siRNA Design

Vector-Based RNAi Segment by Application

Hospitals

Speciality Clinics

Vector-Based RNAi Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vector-Based RNAi market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vector-Based RNAi and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vector-Based RNAi.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vector-Based RNAi manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vector-Based RNAi in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Custom siRNA Construction Table 2. Major Company of siRNA Vectors Table 3. Major Company of siRNA Design Table 4. Global Vector-Based RNAi Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vector-Based RNAi Sales by Type (2021-2026) & (K Units) Table 6. Global Vector-Based RNAi Sales Market Share in Volume by Type (2021-2026) Table 7. Global Vector-Based RNAi Sales by Type (2021-2026) & (US$ Million) Table 8. Global Vector-Based RNAi Sales Market Share in Value by Type (2021-2026) Table 9. Global Vector-Based RNAi Price by Type (2021-2026) & (US$/Unit) Table 10. Global Vector-Based RNAi Sales by Type (2027-2032) & (K Units) Table 11. Global Vector-Based RNAi Sales Market Share in Volume by Type (2027-2032) Table 12. Global Vector-Based RNAi Sales by Type (2027-2032) & (US$ Million) Table 13. Global Vector-Based RNAi Sales Market Share in Value by Type (2027-2032) Table 14. Global Vector-Based RNAi Price by Type (2027-2032) & (US$/Unit) Table 15. North America Vector-Based RNAi Sales by Type (2021-2026) & (K Units) Table 16. North America Vector-Based RNAi Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Vector-Based RNAi Sales by Type (2021-2026) & (K Units) Table 18. Europe Vector-Based RNAi Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Vector-Based RNAi Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Vector-Based RNAi Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Vector-Based RNAi Sales by Type (2021-2026) & (K Units) Table 22. Latin America Vector-Based RNAi Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Vector-Based RNAi Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Vector-Based RNAi Sales by Type (2021-2026) & (US$ Million) Table 25. Vector-Based RNAi Industry Trends Table 26. Vector-Based RNAi Industry Drivers Table 27. Vector-Based RNAi Industry Opportunities and Challenges Table 28. Vector-Based RNAi Industry Restraints Table 29. Global Vector-Based RNAi Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Vector-Based RNAi Revenue Market Share by Company (2021-2026) Table 31. Global Vector-Based RNAi Sales by Company (2021-2026) & (K Units) Table 32. Global Vector-Based RNAi Sales Share by Company (2021-2026) Table 33. Global Vector-Based RNAi Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Vector-Based RNAi Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Vector-Based RNAi Major Company Production Sites and Headquarters Table 36. Global Vector-Based RNAi Company, Product Type & Application Table 37. Global Vector-Based RNAi Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Vector-Based RNAi by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Vector-Based RNAi Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Vector-Based RNAi Sales by Region (2021-2026) & (K Units) Table 42. Global Vector-Based RNAi Sales Market Share in Volume by Region (2021-2026) Table 43. Global Vector-Based RNAi Sales by Region (2021-2026) & (US$ Million) Table 44. Global Vector-Based RNAi Sales Market Share in Value by Region (2021-2026) Table 45. Global Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Vector-Based RNAi Sales by Region (2027-2032) & (K Units) Table 47. Global Vector-Based RNAi Sales Market Share in Volume by Region (2027-2032) Table 48. Global Vector-Based RNAi Sales by Region (2027-2032) & (US$ Million) Table 49. Global Vector-Based RNAi Sales Market Share in Value by Region (2027-2032) Table 50. Global Vector-Based RNAi Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Vector-Based RNAi Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Vector-Based RNAi Sales by Application (2021-2026) & (K Units) Table 53. Global Vector-Based RNAi Sales Market Share in Volume by Application (2021-2026) Table 54. Global Vector-Based RNAi Sales by Application (2021-2026) & (US$ Million) Table 55. Global Vector-Based RNAi Sales Market Share in Value by Application (2021-2026) Table 56. Global Vector-Based RNAi Price by Application (2021-2026) & (US$/Unit) Table 57. Global Vector-Based RNAi Sales by Application (2027-2032) & (K Units) Table 58. Global Vector-Based RNAi Sales Market Share in Volume by Application (2027-2032) Table 59. Global Vector-Based RNAi Sales by Application (2027-2032) & (US$ Million) Table 60. Global Vector-Based RNAi Sales Market Share in Value by Application (2027-2032) Table 61. Global Vector-Based RNAi Price by Application (2027-2032) & (US$/Unit) Table 62. North America Vector-Based RNAi Sales by Application (2021-2026) & (K Units) Table 63. North America Vector-Based RNAi Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Vector-Based RNAi Sales by Application (2021-2026) & (K Units) Table 65. Europe Vector-Based RNAi Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Vector-Based RNAi Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Vector-Based RNAi Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Vector-Based RNAi Sales by Application (2021-2026) & (K Units) Table 69. Latin America Vector-Based RNAi Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Vector-Based RNAi Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Vector-Based RNAi Sales by Application (2021-2026) & (US$ Million) Table 72. Alnylam Pharmaceuticals Company Information Table 73. Alnylam Pharmaceuticals Business Overview Table 74. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolio Table 76. Alnylam Pharmaceuticals Recent Development Table 77. Arcturus Therapeutics Company Information Table 78. Arcturus Therapeutics Business Overview Table 79. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Arcturus Therapeutics Vector-Based RNAi Product Portfolio Table 81. Arcturus Therapeutics Recent Development Table 82. Arrowhead Pharmaceuticals Company Information Table 83. Arrowhead Pharmaceuticals Business Overview Table 84. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolio Table 86. Arrowhead Pharmaceuticals Recent Development Table 87. Dicerna Pharmaceuticals Company Information Table 88. Dicerna Pharmaceuticals Business Overview Table 89. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolio Table 91. Dicerna Pharmaceuticals Recent Development Table 92. Ionis Pharmaceutical Company Information Table 93. Ionis Pharmaceutical Business Overview Table 94. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Ionis Pharmaceutical Vector-Based RNAi Product Portfolio Table 96. Ionis Pharmaceutical Recent Development Table 97. Phio Pharmaceutical Company Information Table 98. Phio Pharmaceutical Business Overview Table 99. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Phio Pharmaceutical Vector-Based RNAi Product Portfolio Table 101. Phio Pharmaceutical Recent Development Table 102. Qiagen NV Company Information Table 103. Qiagen NV Business Overview Table 104. Qiagen NV Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Qiagen NV Vector-Based RNAi Product Portfolio Table 106. Qiagen NV Recent Development Table 107. Quark Pharmaceuticals Company Information Table 108. Quark Pharmaceuticals Business Overview Table 109. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Quark Pharmaceuticals Vector-Based RNAi Product Portfolio Table 111. Quark Pharmaceuticals Recent Development Table 112. Silence Therapeutics Company Information Table 113. Silence Therapeutics Business Overview Table 114. Silence Therapeutics Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Silence Therapeutics Vector-Based RNAi Product Portfolio Table 116. Silence Therapeutics Recent Development Table 117. Merck & Co. Company Information Table 118. Merck & Co. Business Overview Table 119. Merck & Co. Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Merck & Co. Vector-Based RNAi Product Portfolio Table 121. Merck & Co. Recent Development Table 122. Thermo Fisher Scientific Company Information Table 123. Thermo Fisher Scientific Business Overview Table 124. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Thermo Fisher Scientific Vector-Based RNAi Product Portfolio Table 126. Thermo Fisher Scientific Recent Development Table 127. North America Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. North America Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 129. North America Vector-Based RNAi Sales Market Share by Country (2021-2026) Table 130. North America Vector-Based RNAi Sales Forecast by Country (2027-2032) & (K Units) Table 131. North America Vector-Based RNAi Sales Market Share Forecast by Country (2027-2032) Table 132. North America Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. North America Vector-Based RNAi Market Size by Country (2021-2026) & (US$ Million) Table 134. North America Vector-Based RNAi Market Share by Country (2021-2026) Table 135. North America Vector-Based RNAi Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. North America Vector-Based RNAi Market Share Forecast by Country (2027-2032) Table 137. Europe Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Europe Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 139. Europe Vector-Based RNAi Sales Market Share by Country (2021-2026) Table 140. Europe Vector-Based RNAi Sales Forecast by Country (2027-2032) & (K Units) Table 141. Europe Vector-Based RNAi Sales Market Share Forecast by Country (2027-2032) Table 142. Europe Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Europe Vector-Based RNAi Market Size by Country (2021-2026) & (US$ Million) Table 144. Europe Vector-Based RNAi Market Share by Country (2021-2026) Table 145. Europe Vector-Based RNAi Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Europe Vector-Based RNAi Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 149. Asia-Pacific Vector-Based RNAi Sales Market Share by Country (2021-2026) Table 150. Asia-Pacific Vector-Based RNAi Sales Forecast by Country (2027-2032) & (K Units) Table 151. Asia-Pacific Vector-Based RNAi Sales Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific Vector-Based RNAi Market Size by Country (2021-2026) & (US$ Million) Table 154. Asia-Pacific Vector-Based RNAi Market Share by Country (2021-2026) Table 155. Asia-Pacific Vector-Based RNAi Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Asia-Pacific Vector-Based RNAi Market Share Forecast by Country (2027-2032) Table 157. Latin America Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 158. Latin America Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 159. Latin America Vector-Based RNAi Sales Market Share by Country (2021-2026) Table 160. Latin America Vector-Based RNAi Sales Forecast by Country (2027-2032) & (K Units) Table 161. Latin America Vector-Based RNAi Sales Market Share Forecast by Country (2027-2032) Table 162. Latin America Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Latin America Vector-Based RNAi Market Size by Country (2021-2026) & (US$ Million) Table 164. Latin America Vector-Based RNAi Market Share by Country (2021-2026) Table 165. Latin America Vector-Based RNAi Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Latin America Vector-Based RNAi Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Vector-Based RNAi Sales by Country (2021-2026) & (K Units) Table 169. Middle East and Africa Vector-Based RNAi Sales Market Share by Country (2021-2026) Table 170. Middle East and Africa Vector-Based RNAi Sales Forecast by Country (2027-2032) & (K Units) Table 171. Middle East and Africa Vector-Based RNAi Sales Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa Vector-Based RNAi Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa Vector-Based RNAi Market Size by Country (2021-2026) & (US$ Million) Table 174. Middle East and Africa Vector-Based RNAi Market Share by Country (2021-2026) Table 175. Middle East and Africa Vector-Based RNAi Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Middle East and Africa Vector-Based RNAi Market Share Forecast by Country (2027-2032) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Vector-Based RNAi Distributors List Table 180. Vector-Based RNAi Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Vector-Based RNAi Image Figure 2. Global Vector-Based RNAi Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vector-Based RNAi Market Size (2021-2032) & (US$ Million) Figure 4. Global Vector-Based RNAi Sales (2021-2032) & (K Units) Figure 5. Custom siRNA Construction Image Figure 6. Global Custom siRNA Construction Sales YoY Growth (2021-2032) & (K Units) Figure 7. siRNA Vectors Image Figure 8. Global siRNA Vectors Sales YoY Growth (2021-2032) & (K Units) Figure 9. siRNA Design Image Figure 10. Global siRNA Design Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Vector-Based RNAi Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Vector-Based RNAi Market Share by Type 2025 VS 2032 Figure 13. North America Vector-Based RNAi Sales Market Share in Volume by Type in 2025 Figure 14. North America Vector-Based RNAi Sales Market Share in Value by Type in 2025 Figure 15. Europe Vector-Based RNAi Sales Market Share in Volume by Type in 2025 Figure 16. Europe Vector-Based RNAi Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Vector-Based RNAi Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Vector-Based RNAi Sales Market Share in Value by Type in 2025 Figure 19. Latin America Vector-Based RNAi Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Vector-Based RNAi Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Vector-Based RNAi Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Vector-Based RNAi Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Vector-Based RNAi Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospitals Image Figure 26. Global Hospitals Sales YoY Growth (2021-2032) & (K Units) Figure 27. Speciality Clinics Image Figure 28. Global Speciality Clinics Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Vector-Based RNAi Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Vector-Based RNAi Market Share by Application 2025 VS 2032 Figure 31. North America Vector-Based RNAi Sales Market Share in Volume by Application in 2025 Figure 32. North America Vector-Based RNAi Sales Market Share in Value by Application in 2025 Figure 33. Europe Vector-Based RNAi Sales Market Share in Volume by Application in 2025 Figure 34. Europe Vector-Based RNAi Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Vector-Based RNAi Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Vector-Based RNAi Sales Market Share in Value by Application in 2025 Figure 37. Latin America Vector-Based RNAi Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Vector-Based RNAi Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Vector-Based RNAi Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Vector-Based RNAi Sales Market Share in Value by Application in 2025 Figure 41. North America Vector-Based RNAi Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Vector-Based RNAi Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Vector-Based RNAi Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Vector-Based RNAi Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Vector-Based RNAi Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Vector-Based RNAi Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Vector-Based RNAi Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Vector-Based RNAi Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Vector-Based RNAi Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Vector-Based RNAi Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Vector-Based RNAi Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Vector-Based RNAi Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Vector-Based RNAi Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Vector-Based RNAi Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Vector-Based RNAi Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Vector-Based RNAi Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Vector-Based RNAi Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Custom siRNA Construction
  • siRNA Vectors
  • siRNA Design
Applications
  • Hospitals
  • Speciality Clinics
Companies covered
  • Alnylam Pharmaceuticals
  • Arcturus Therapeutics
  • Arrowhead Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Ionis Pharmaceutical
  • Phio Pharmaceutical
  • Qiagen NV
  • Quark Pharmaceuticals
  • Silence Therapeutics
  • Merck & Co.
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vector-Based RNAi Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vector-Based RNAi Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vector-Based RNAi Market by Type
  6. 1.3.1 Custom siRNA Construction
  7. 1.3.2 siRNA Vectors
  8. 1.3.3 siRNA Design
  9. 1.4 Global Vector-Based RNAi Market Size by Type
  10. 1.4.1 Global Vector-Based RNAi Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Vector-Based RNAi Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Vector-Based RNAi Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Vector-Based RNAi Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Vector-Based RNAi Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Vector-Based RNAi Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Vector-Based RNAi Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Vector-Based RNAi Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vector-Based RNAi Industry Trends
  2. 2.2 Vector-Based RNAi Industry Drivers
  3. 2.3 Vector-Based RNAi Industry Opportunities and Challenges
  4. 2.4 Vector-Based RNAi Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vector-Based RNAi Revenue (2021-2026)
  2. 3.2 Global Top Players by Vector-Based RNAi Sales (2021-2026)
  3. 3.3 Global Top Players by Vector-Based RNAi Price (2021-2026)
  4. 3.4 Global Vector-Based RNAi Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vector-Based RNAi Major Company Production Sites & Headquarters
  6. 3.6 Global Vector-Based RNAi Company, Product Type & Application
  7. 3.7 Global Vector-Based RNAi Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vector-Based RNAi Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vector-Based RNAi Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vector-Based RNAi Tier 1, Tier 2, and Tier 3
4 Vector-Based RNAi Regional Status and Outlook
  1. 4.1 Global Vector-Based RNAi Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vector-Based RNAi Historic Market Size by Region
  3. 4.2.1 Global Vector-Based RNAi Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vector-Based RNAi Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vector-Based RNAi Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vector-Based RNAi Forecasted Market Size by Region
  7. 4.3.1 Global Vector-Based RNAi Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vector-Based RNAi Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vector-Based RNAi Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vector-Based RNAi by Application
  1. 5.1 Vector-Based RNAi Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Speciality Clinics
  4. 5.2 Global Vector-Based RNAi Market Size by Application
  5. 5.2.1 Global Vector-Based RNAi Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Vector-Based RNAi Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Vector-Based RNAi Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Vector-Based RNAi Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Vector-Based RNAi Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Vector-Based RNAi Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Vector-Based RNAi Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Vector-Based RNAi Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Alnylam Pharmaceuticals
  2. 6.1.1 Alnylam Pharmaceuticals Company Information
  3. 6.1.2 Alnylam Pharmaceuticals Business Overview
  4. 6.1.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolio
  6. 6.1.5 Alnylam Pharmaceuticals Recent Developments
  7. 6.2 Arcturus Therapeutics
  8. 6.2.1 Arcturus Therapeutics Company Information
  9. 6.2.2 Arcturus Therapeutics Business Overview
  10. 6.2.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Arcturus Therapeutics Vector-Based RNAi Product Portfolio
  12. 6.2.5 Arcturus Therapeutics Recent Developments
  13. 6.3 Arrowhead Pharmaceuticals
  14. 6.3.1 Arrowhead Pharmaceuticals Company Information
  15. 6.3.2 Arrowhead Pharmaceuticals Business Overview
  16. 6.3.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolio
  18. 6.3.5 Arrowhead Pharmaceuticals Recent Developments
  19. 6.4 Dicerna Pharmaceuticals
  20. 6.4.1 Dicerna Pharmaceuticals Company Information
  21. 6.4.2 Dicerna Pharmaceuticals Business Overview
  22. 6.4.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolio
  24. 6.4.5 Dicerna Pharmaceuticals Recent Developments
  25. 6.5 Ionis Pharmaceutical
  26. 6.5.1 Ionis Pharmaceutical Company Information
  27. 6.5.2 Ionis Pharmaceutical Business Overview
  28. 6.5.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Ionis Pharmaceutical Vector-Based RNAi Product Portfolio
  30. 6.5.5 Ionis Pharmaceutical Recent Developments
  31. 6.6 Phio Pharmaceutical
  32. 6.6.1 Phio Pharmaceutical Company Information
  33. 6.6.2 Phio Pharmaceutical Business Overview
  34. 6.6.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Phio Pharmaceutical Vector-Based RNAi Product Portfolio
  36. 6.6.5 Phio Pharmaceutical Recent Developments
  37. 6.7 Qiagen NV
  38. 6.7.1 Qiagen NV Company Information
  39. 6.7.2 Qiagen NV Business Overview
  40. 6.7.3 Qiagen NV Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Qiagen NV Vector-Based RNAi Product Portfolio
  42. 6.7.5 Qiagen NV Recent Developments
  43. 6.8 Quark Pharmaceuticals
  44. 6.8.1 Quark Pharmaceuticals Company Information
  45. 6.8.2 Quark Pharmaceuticals Business Overview
  46. 6.8.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Quark Pharmaceuticals Vector-Based RNAi Product Portfolio
  48. 6.8.5 Quark Pharmaceuticals Recent Developments
  49. 6.9 Silence Therapeutics
  50. 6.9.1 Silence Therapeutics Company Information
  51. 6.9.2 Silence Therapeutics Business Overview
  52. 6.9.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Silence Therapeutics Vector-Based RNAi Product Portfolio
  54. 6.9.5 Silence Therapeutics Recent Developments
  55. 6.10 Merck & Co.
  56. 6.10.1 Merck & Co. Company Information
  57. 6.10.2 Merck & Co. Business Overview
  58. 6.10.3 Merck & Co. Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Merck & Co. Vector-Based RNAi Product Portfolio
  60. 6.10.5 Merck & Co. Recent Developments
  61. 6.11 Thermo Fisher Scientific
  62. 6.11.1 Thermo Fisher Scientific Company Information
  63. 6.11.2 Thermo Fisher Scientific Business Overview
  64. 6.11.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Thermo Fisher Scientific Vector-Based RNAi Product Portfolio
  66. 6.11.5 Thermo Fisher Scientific Recent Developments
7 North America by Country
  1. 7.1 North America Vector-Based RNAi Sales by Country
  2. 7.1.1 North America Vector-Based RNAi Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vector-Based RNAi Sales by Country (2021-2026)
  4. 7.1.3 North America Vector-Based RNAi Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vector-Based RNAi Market Size by Country
  6. 7.2.1 North America Vector-Based RNAi Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vector-Based RNAi Market Size by Country (2021-2026)
  8. 7.2.3 North America Vector-Based RNAi Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vector-Based RNAi Sales by Country
  2. 8.1.1 Europe Vector-Based RNAi Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vector-Based RNAi Sales by Country (2021-2026)
  4. 8.1.3 Europe Vector-Based RNAi Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vector-Based RNAi Market Size by Country
  6. 8.2.1 Europe Vector-Based RNAi Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vector-Based RNAi Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vector-Based RNAi Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vector-Based RNAi Sales by Country
  2. 9.1.1 Asia-Pacific Vector-Based RNAi Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vector-Based RNAi Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vector-Based RNAi Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vector-Based RNAi Market Size by Country
  6. 9.2.1 Asia-Pacific Vector-Based RNAi Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vector-Based RNAi Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vector-Based RNAi Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vector-Based RNAi Sales by Country
  2. 10.1.1 South America Vector-Based RNAi Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vector-Based RNAi Sales by Country (2021-2026)
  4. 10.1.3 South America Vector-Based RNAi Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vector-Based RNAi Market Size by Country
  6. 10.2.1 South America Vector-Based RNAi Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vector-Based RNAi Market Size by Country (2021-2026)
  8. 10.2.3 South America Vector-Based RNAi Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vector-Based RNAi Sales by Country
  2. 11.1.1 Middle East and Africa Vector-Based RNAi Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vector-Based RNAi Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vector-Based RNAi Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vector-Based RNAi Market Size by Country
  6. 11.2.1 Middle East and Africa Vector-Based RNAi Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vector-Based RNAi Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vector-Based RNAi Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vector-Based RNAi Value Chain Analysis
  2. 12.1.1 Vector-Based RNAi Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vector-Based RNAi Production Mode & Process
  7. 12.2 Vector-Based RNAi Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vector-Based RNAi Distributors
  10. 12.2.3 Vector-Based RNAi Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst